Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

"Explosion in cancer genome": much more common than expected

No. 37c3 | 04/06/2020 | by Koh

Chromothripsis is a form of genome instability by which one or a few chromosomes virtually "explode(s)" in a presumably single catastrophic event. According to current opinion, chromothripsis occurs at the beginning of tumor development and plays an important role in cancer onset. While the phenomenon was previously considered to be rather rare, scientists at the German Cancer Research Center have now shown that chromothripsis is detectable in almost half of all tumors.

© Adobe Stock

The damage pattern of "chromothripsis", which has only been known for about ten years, differs from previously known genetic defects in tumor cells. Sections of one or a few chromosomes are broken in countless places and reassembled in an irregular manner, so that entire sections of the genetic material are missing, while others are duplicated or inserted in the wrong orientation.

Until now, it has been assumed that this genetic disaster occurs in only two to three percent of cancer cases. However, in a recent study, scientists led by Aurélie Ernst at the German Cancer Research Center (DKFZ) are now using highly sensitive analytical methods to show that the frequency of chromothripsis has so far been considerably underestimated. In collaboration with the NCT/DKTK MASTER program, the DKFZ researchers examined 634 tumor samples from 28 different types of cancer, covering all major cancers in adults. They found traces of the chromosome explosion in 49 percent of all patients examined.

Chromothripsis was particularly frequent in tumors of patients who had inherited a mutation from their parents that predisposes them to develop cancer. In addition, in various types of cancer chromothripsis occurred more frequently in certain chromosomal regions than would be the case with a purely random distribution. The researchers conclude from this that in these cases the chromosome explosion gives the cells a survival advantage.

In addition, the scientists gained important insights into the evolution of tumors: Previously, they had suspected that chromothripsis usually occurs at the very beginning of the tumorigenesis or even initiates cancer onset. But the current results paint a different picture: In patients from whom tumor samples were taken several times during the course of the disease, it was found that in some cases only individual subclones were affected by the chromosomal disaster. In other cases, the researchers found chromothripsis only in the tumor relapse, but not in the primary tumor.

Of high clinical relevance is the observation that chromothripsis often generates fusions of chromosomal fragments that promote tumor development. This may, for example, be due to the fact that a growth-promoting gene comes under the influence of a strong activator as a result of the fusion. "A number of scientific publications have already shown that in such cases, it is sometimes possible to slow down tumor growth with targeted drugs," explains senior author Aurélie Ernst.

The landscape of chromothripsis across adult cancer types. Voronina N, Wong JKL, Hübschmann D, Hlevnjak M, Sebastian Uhrig S, Heilig CE, Horak P, Kreutzfeldt S, Mock A, Stenzinger A, Hutter B, Fröhlich M, Brors B, Jahn A, Klink B, Gieldon L, Sieverling L, Feuerbach L, Priya Chudasama P, Beck K, Kroiss M, Heining C, Möhrmann L, Fischer A, Schröck E, Glimm H, Zapatka M, Lichter P, Fröhling S and Ernst A.
Nature Communications 2020, DOI 10.1038/s41467-020-16134-7

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institution in Germany. More than 1,300 scientists at the DKFZ investigate how cancer develops, identify cancer risk factors and search for new strategies to prevent people from developing cancer. They are developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to all questions on cancer.

Jointly with partners from the university hospitals, the DKFZ operates the National Center for Tumor Diseases (NCT) in Heidelberg and Dresden, and the Hopp Children's Cancer Center KiTZ in Heidelberg. In the German Consortium for Translational Cancer Research (DKTK), one of the six German Centers for Health Research, the DKFZ maintains translational centers at seven university partner locations. NCT and DKTK sites combine excellent university medicine with the high-profile research of the DKFZ. They contribute to the endeavor of transferring promising approaches from cancer research to the clinic and thus improving the chances of cancer patients.

The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS